1 Reason This Biotech Stock Could Triple Before Year-End

1 Reason This Biotech Stock Could Triple Before Year-End

Key PointsViking Therepeutics' VK2735 candidate is a dark horse contender among GLP-1 weight loss drugs.If upcoming late-stage clinical trial results prove positive, Viking's value as a takeover target could rise exponentially.While risky, Viking's high upside potential, along with the relatively short path to its "moment of truth," may make it worthwhile as a small, speculative position.10 stocks we like better than Viking Therapeutics › When y…